Facebook and pharma in 2014
Ten years on, Facebook remains an important channel through which pharma can engage with patients. What has been learned in that time and how have communication strategies evolved within the boundaries of industry regulation?
In 10 short years, Facebook has amassed 1.35 billion monthly active users, allowing people to not only interact with their friends, but also with their favourite brands. Although some pharma companies established their presence early on, they were simply maintaining a one-way communicative stance, in contrast to less regulated industries, mainly because of the absence of guidelines on new digital platforms from regulatory bodies.
While some carefully dipped their toes into more customer engagement without attracting any negative attention, others received stern warning letters from regulators like the US Food and Drug Administration (FDA). Now in 2014, the FDA continues to issue warnings for incomplete drug information on Facebook, and the platform still presents a tough environment for the industry to navigate, especially when it comes to having meaningful engagement.
Now that they have more guidance from the authorities about how they should conduct themselves in the digital space, pharma companies’ presence on Facebook warrants a fresh look.
How is pharma using Facebook?
Judging by the amount of likes on their Facebook pages, the most popular companies on Facebook are: Johnson & Johnson (J&J), Boehringer Ingelheim (BI), Pfizer, GlaxoSmithKline (GSK) and Novartis. While it is not the most important metric in effective engagement, it is still indicative of a company’s reach across the network.
Of course, in social media the number of followers, fans, or likes is meaningless if there is no real conversation or sharing taking place. Overall, the type of content posted on the pages is fairly similar between these companies.
Currently the posts consist of:
• Company news and corporate social responsibility actions
• Company events
• Past or present stories about developments in healthcare in general
• Stories about real patients, doctors, or employees
• International days for disease areas, such as World Pneumonia Day (12 November)
• Career opportunities.
Many of these are successful in engaging their audience, considering that there are several likes and shares on each post, as well as some being commented on (especially if they are topical, like Ebola). More robust engagement comes in the form of competitions, such as BI’s asthma photography contest. This gets people involved in creating content as well as raising awareness of a therapy area without being promotional and involving product names.
Going one step further, J&J not only asks general questions to the fans of the page, but is also involved in the follow-up discussions. Having personal responses from the company is of high value to the customers, and the dialogue helps build reputation. Note that the key to avoiding regulatory issues is to ask something that is not likely to lead to any mention of products or adverse events.
Regulations within the industry mean that comments may be removed and most pharmaceutical firms on Facebook have disclaimers on their pages stating that this may be a result of referencing drugs or their effects. This is made most clear by having a different visible tab on the page labelled ‘Community Guidelines’ or ‘Comment Missing?’ as done on the pages of J&J, Pfizer, and Novartis. Having an easy-to-understand and friendly section on these terms helps alleviate any customer frustration.
The importance of engagement
This is just a small glimpse into how pharmaceutical companies are using Facebook in their messaging to the public. Although the medium may seem constraining, there is still room for creativity in providing compelling information while remaining compliant. The easiest way to promote participation and interaction with the company is through contests, quizzes, conversations about daily life, games and other activities that go beyond the ‘like’.
As mentioned earlier, Facebook has allowed users to not only chat with their friends, but also with companies. However, the ultimate goal should be that these companies become friends through open dialogue with their consumers and transparency regarding their regulatory situation, in order to gain the trust and support of the people they serve.
About the author:
Stefan Marcus is research strategist with Creation Healthcare, the engagement strategy consultancy to the global healthcare industry with a special interest in the digital behaviours of health stakeholders.
Have your say: How can pharma better engage through Facebook?
Read more from Creation Healthcare: